This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hasmann, M. Articles by Schemainda, I. Search for Related Content PubMed PubMed Citation Articles by Hasmann, M. Articles by Schemainda, I.

FK866, a Highly Specific Noncompetitive Inhibitor of Nicotinamide Phosphoribosyltransferase, Represents a Novel Mechanism for Induction of Tumor Cell Apoptosis

Fujisawa GmbH, 81673 Munich, Germany

Deregulation of apoptosis, the physiological form of cell death, is closely associated with immunological diseases and cancer. Apoptosis is activated either by death receptor-driven or mitochondrial pathways, both of which may provide potential targets for novel anticancer drugs. Although several ligands stimulating death receptors have been described, the actual molecular events triggering the mitochondrial pathway are largely unknown. Here, we show initiation of apoptosis by gradual depletion of the intracellular coenzyme NAD⁺. We identified the first low molecular weight compound, designated FK866, which induces apoptosis by highly specific, noncompetitive inhibition of nicotinamide phosphoribosyltransferase (NAPRT), a key enzyme in the regulation of NAD⁺ biosynthesis from the natural precursor nicotinamide. Interference with this enzyme does not primarily intoxicate cells because the mitochondrial respiratory activity and the NAD⁺-dependent redox reactions involved remain unaffected as long as NAD⁺ is not effectively depleted by catabolic reactions. Certain tissues, however, have a high turnover of NAD⁺ through its cleavage by enzymes like poly(ADP-ribose) polymerase. Such cells often rely on the more readily available nicotinamide pathway for NAD⁺ synthesis and undergo apoptosis after inhibition of NAPRT, whereas cells effectively using the nicotinic acid pathway for NAD⁺ synthesis remain unaffected. In support of this concept, FK866 effectively induced delayed cell death by apoptosis in HepG2 human liver carcinoma cells with an IC₅₀ of 1 nM, did not directly inhibit mitochondrial respiratory activity, but caused gradual NAD⁺ depletion through specific inhibition of NAPRT. This enzyme, when partially purified from K562 human leukemia cells, was noncompetitively inhibited by FK866, and the inhibitor constants were calculated to be 0.4 nM for the enzyme/substrate complex (K_i) and 0.3 nM for the free enzyme (K_i'), respectively. Nicotinic acid and nicotinamide were both found to have antidote potential for the cellular effects of FK866. FK866 may be used for treatment of diseases implicating deregulated apoptosis such as cancer for immunosuppression or as a sensitizer for genotoxic agents. Furthermore, it may provide an important tool for investigation of the molecular triggers of the mitochondrial pathway leading to apoptosis through enabling temporal separation of NAD⁺ decrease from ATP breakdown and apoptosis by several days.

This article has been cited by other articles:

				L. Formentini, A. Macchiarulo, G. Cipriani, E. Camaioni, E. Rapizzi, R. Pellicciari, F. Moroni, and A. Chiarugi Poly(ADP-ribose) Catabolism Triggers AMP-dependent Mitochondrial Energy Failure J. Biol. Chem., June 26, 2009; 284(26): 17668 - 17676. [Abstract] [Full Text] [PDF]

				M. Cea, G. Zoppoli, S. Bruzzone, F. Fruscione, E. Moran, A. Garuti, I. Rocco, G. Cirmena, S. Casciaro, F. Olcese, et al. APO866 activity in hematologic malignancies: a preclinical in vitro study Blood, June 4, 2009; 113(23): 6035 - 6037. [Full Text] [PDF]

				F.-M. Lin, B. Qiao, and Y.-J. Yuan Comparative Proteomic Analysis of Tolerance and Adaptation of Ethanologenic Saccharomyces cerevisiae to Furfural, a Lignocellulosic Inhibitory Compound Appl. Envir. Microbiol., June 1, 2009; 75(11): 3765 - 3776. [Abstract] [Full Text] [PDF]

				Y. Nakahata, S. Sahar, G. Astarita, M. Kaluzova, and P. Sassone-Corsi Circadian Control of the NAD+ Salvage Pathway by CLOCK-SIRT1 Science, May 1, 2009; 324(5927): 654 - 657. [Abstract] [Full Text] [PDF]

				K. M. Ramsey, J. Yoshino, C. S. Brace, D. Abrassart, Y. Kobayashi, B. Marcheva, H.-K. Hong, J. L. Chong, E. D. Buhr, C. Lee, et al. Circadian Clock Feedback Cycle Through NAMPT-Mediated NAD+ Biosynthesis Science, May 1, 2009; 324(5927): 651 - 654. [Abstract] [Full Text] [PDF]

				Y. Sasaki, B. P. S. Vohra, F. E. Lund, and J. Milbrandt Nicotinamide Mononucleotide Adenylyl Transferase-Mediated Axonal Protection Requires Enzymatic Activity But Not Increased Levels of Neuronal Nicotinamide Adenine Dinucleotide J. Neurosci., April 29, 2009; 29(17): 5525 - 5535. [Abstract] [Full Text] [PDF]

				A. Nahimana, A. Attinger, D. Aubry, P. Greaney, C. Ireson, A. V. Thougaard, J. Tjornelund, K. M. Dawson, M. Dupuis, and M. A. Duchosal The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies Blood, April 2, 2009; 113(14): 3276 - 3286. [Abstract] [Full Text] [PDF]

				P. Wang, T.-Y. Xu, Y.-F. Guan, D.-F. Su, G.-R. Fan, and C.-Y. Miao Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide Cardiovasc Res, February 1, 2009; 81(2): 370 - 380. [Abstract] [Full Text] [PDF]

				J. L. Spratlin, N. J. Serkova, and S. G. Eckhardt Clinical Applications of Metabolomics in Oncology: A Review Clin. Cancer Res., January 15, 2009; 15(2): 431 - 440. [Abstract] [Full Text] [PDF]

				M. Dvir-Ginzberg, V. Gagarina, E.-J. Lee, and D. J. Hall Regulation of Cartilage-specific Gene Expression in Human Chondrocytes by SirT1 and Nicotinamide Phosphoribosyltransferase J. Biol. Chem., December 26, 2008; 283(52): 36300 - 36310. [Abstract] [Full Text] [PDF]

				H. K. Song, M. H. Lee, B. K. Kim, Y. G. Park, G. J. Ko, Y. S. Kang, J. Y. Han, S. Y. Han, K. H. Han, H. K. Kim, et al. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy Am J Physiol Renal Physiol, November 1, 2008; 295(5): F1485 - F1494. [Abstract] [Full Text] [PDF]

				W.-L. Yen and D. J. Klionsky How to Live Long and Prosper: Autophagy, Mitochondria, and Aging Physiology, October 1, 2008; 23(5): 248 - 262. [Abstract] [Full Text] [PDF]

				A. Rongvaux, M. Galli, S. Denanglaire, F. Van Gool, P. L. Dreze, C. Szpirer, F. Bureau, F. Andris, and O. Leo Nicotinamide Phosphoribosyl Transferase/Pre-B Cell Colony-Enhancing Factor/Visfatin Is Required for Lymphocyte Development and Cellular Resistance to Genotoxic Stress J. Immunol., October 1, 2008; 181(7): 4685 - 4695. [Abstract] [Full Text] [PDF]

				R. A. Billington, C. Travelli, E. Ercolano, U. Galli, C. B. Roman, A. A. Grolla, P. L. Canonico, F. Condorelli, and A. A. Genazzani Characterization of NAD Uptake in Mammalian Cells J. Biol. Chem., March 7, 2008; 283(10): 6367 - 6374. [Abstract] [Full Text] [PDF]

				N. Hara, K. Yamada, T. Shibata, H. Osago, T. Hashimoto, and M. Tsuchiya Elevation of Cellular NAD Levels by Nicotinic Acid and Involvement of Nicotinic Acid Phosphoribosyltransferase in Human Cells J. Biol. Chem., August 24, 2007; 282(34): 24574 - 24582. [Abstract] [Full Text] [PDF]

				E. van der Veer, C. Ho, C. O'Neil, N. Barbosa, R. Scott, S. P. Cregan, and J. G. Pickering Extension of Human Cell Lifespan by Nicotinamide Phosphoribosyltransferase J. Biol. Chem., April 13, 2007; 282(15): 10841 - 10845. [Abstract] [Full Text] [PDF]

				M. Muruganandham, A. A. Alfieri, C. Matei, Y. Chen, G. Sukenick, I. Schemainda, M. Hasmann, L. B. Saltz, and J. A. Koutcher Metabolic Signatures Associated with a NAD Synthesis Inhibitor-Induced Tumor Apoptosis Identified by 1H-Decoupled-31P Magnetic Resonance Spectroscopy Clin. Cancer Res., May 1, 2005; 11(9): 3503 - 3513. [Abstract] [Full Text] [PDF]